A+ R A-

Therapeutics in WM: Thalidomide

Please select from the following list of abstracts, representing presentations given at Athens 2002 (IWWM-2) Session 7:

Bone Marrow angiogenesis in Waldenstroms Macroglobulinemia (WM). S. Vincent Rajkumar, Suzanne Hayman, and Philip Greipp.

Thalidomide-based treatment for Waldenstrom's macroglobulinemia. M.A. Dimopoulos, A. Zomas, K. Tsatalas, G Hamilos, E. Efstathiou.

Biaxin, low dose thalidomide, and dexamethasone (BLT-D) are highly active in Waldenstrom's macroglobulinemia. Morton Coleman.

Potential New Pharmaceutics for the Treatment of Waldenstrom's Macroglobulinemia. JB Zeldis.

Rituximab Induced antibody Dependent Cell mediated Cytotoxicity (ADCC) is enhanced by thalidomide and its analogue Revimid. Toshiaki Hayashi, Kenneth Anderson, Steven Treon.